A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

PHASE4CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

May 18, 2022

Primary Completion Date

August 8, 2024

Study Completion Date

August 8, 2024

Conditions
HIV Infections
Interventions
DRUG

APRETUDE

Available as intramuscular injection.

DRUG

Cabotegravir OLI

Available as marketed orally administered tablets.

Trial Locations (17)

10467

GSK Investigational Site, The Bronx

14607

GSK Investigational Site, Rochester

19123

GSK Investigational Site, Philadelphia

20005

GSK Investigational Site, Washington D.C.

29407

GSK Investigational Site, Charleston

32503

GSK Investigational Site, Pensacola

32806

GSK Investigational Site, Orlando

33140

GSK Investigational Site, Miami

34237

GSK Investigational Site, Sarasota

63117

GSK Investigational Site, St Louis

65212

GSK Investigational Site, Columbia

78550

GSK Investigational Site, Harlingen

90036

GSK Investigational Site, Los Angeles

94102

GSK Investigational Site, San Francisco

98104

GSK Investigational Site, Seattle

06605

GSK Investigational Site, Bridgeport

02215

GSK Investigational Site, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY